Malignant Pleural Mesothelioma: Recent Advances in Diagnosis, Molecular Characterization, Predictive Markers and Treatment
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Causes, Screening and Diagnosis".
Deadline for manuscript submissions: closed (30 April 2024) | Viewed by 621
Special Issue Editors
2. Thoracic Surgery, IRCCS Humanitas Research Hospital, Via Manzoni 56, Rozzano, 20089 Milan, Italy
Interests: lung cancer; mesothelioma and mediastinal tumors; standard minimally invasive surgery (VATS) and robotic surgery; endoscopy and trachea surgery; lung transplantation
2. Thoracic Surgery, IRCCS Humanitas Research Hospital, Via Manzoni 56, Rozzano, 20089 Milan, Italy
Interests: cancer
Special Issue Information
Dear Colleagues,
Malignant pleural mesothelioma (MPM) is an aggressive neoplasm, which arises from pleural mesothelial cells of the pleura. It is strictly related to asbestos exposure with a latency time of around 20 to 50 years. The global incidence of MPM has continuously risen along with the widespread industrial use of asbestos. MPM is associated with an extremely poor prognosis, considering that a median survival of less than 1 year and a 5-year survival rate of less than 10% are commonly reported. Several aspects of mesothelioma treatment are discussed, in particular, regarding the extent and best type of surgery, radiotherapy, and the role of neoadjuvant or adjuvant treatment.
Recent progress in research and clinical practice has demonstrated evidence relating to molecular pathogenesis and perspectives on potential therapeutic approaches leading to promising treatment, such as immunotherapy, which could be a favorable option for patients with advanced diseases.
This Special Issue is designated to be a comprehensive review of the state-of-the-art advances in scientific research on mesothelioma, including the pathogenesis, diagnosis, and management of MPM, including, but not limited to:
- Diagnosis: histological and molecular characteristics;
- Radiology and tumor response;
- Oncological management;
- Surgery;
- Innovations in radiotherapy;
- Molecular alterations;
- Targeted agents;
- Cellular therapies;
- Prognostic factors;
- Further trials of interest and future perspectives.
Dr. Giuseppe Marulli
Dr. Giuseppe Mangiameli
Dr. Emanuele Voulaz
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- mesothelioma
- pleural disease
- diagnosis
- prediction
- prognosis
- oncology
- surgery